TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Treatment on study will be administered in 14 day cycles.
Treatment on study will be administered in 14 day cycles.
Tracking Information
- NCT #
- NCT04074343
- Collaborators
- Taiho Pharmaceutical Co., Ltd.
- Investigators
- Principal Investigator: Farshid Dayyani, MD, PhD Chao Family Comprehensive Cancer Center
Get Well Soon